Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;113:2861

Free Article
This Article
Free upon publication Free Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles

(Circulation. 2006;113:2861.)
© 2006 American Heart Association, Inc.

Issue Highlights


*    DUAL-CHAMBER VERSUS SINGLE-CHAMBER DETECTION ENHANCEMENTS FOR IMPLANTABLE DEFIBRILLATOR RHYTHM DIAGNOSIS: THE DETECT SUPRAVENTRICULAR TACHYCARDIA STUDY, by Friedman et al.
up arrowTop
*DUAL-CHAMBER VERSUS SINGLE...
down arrowRESIDUAL ARACHIDONIC ACID...
down arrowRISK OF DEATH OR...
down arrowClinician Update
down arrowImages in Cardiovascular...
down arrowCorrespondence
 
Inappropriate shocks due to supraventricular tachycardias (SVT) can adversely affect quality of life in patients with implantable cardioverter defibrillators (ICDs). Incorporation of atrial sensing into an ICD algorithm for arrhythmia identification was compared to ventricular sensing alone in a 400-patient randomized trial. SVTs were common in ICD recipients, accounting for more than 40% of arrhythmia episodes and occurring in more than 30% of patients. Atrial sensing did reduce inappropriate ICD classification of SVT as ventricular tachycardia (VT), but more than 30% of SVTs were still misclassified as VT. Inappropriate shocks were not reduced because of differences in programming of antitachycardia pacing among groups. These findings by Friedman et al show that atrial sensing can improve SVT detection, but also support appropriate programming of antitachycardia pacing to avoid ICD shocks. Dual chamber ICDs are a reasonable consideration for patients who have VTs with rates that may overlap with SVTs, even if the atrial lead is not required for pacing. See p 2871.


*    RESIDUAL ARACHIDONIC ACID-INDUCED PLATELET ACTIVATION VIA AN ADENOSINE DIPHOSPHATE–DEPENDENT BUT CYCLOOXYGENASE-1– AND CYCLOOXYGENASE-2–INDEPENDENT PATHWAY: A 700-PATIENT STUDY OF ASPIRIN RESISTANCE, by Frelinger et al.
up arrowTop
up arrowDUAL-CHAMBER VERSUS SINGLE...
*RESIDUAL ARACHIDONIC ACID...
down arrowRISK OF DEATH OR...
down arrowClinician Update
down arrowImages in Cardiovascular...
down arrowCorrespondence
 
The absolute risk of recurrent vascular events among patients treated with aspirin remains relatively high and has lead to a concept known as "aspirin resistance." Aspirin resistance has been defined as a clinical entity and by altered biomarkers/enhanced platelet function testing. The mechanism for aspirin resistance remains uncertain, however, and is likely multifactorial. In this issue of Circulation, Frelinger and colleagues study 700 patients treated with aspirin who were undergoing cardiac catheterization. They report that aspirin noncompliance or underdosing was a rare event, and that residual platelet activation after aspirin treatment was by a cyclooxygenase-independent pathway. In patients and normal subjects, they found that platelet activation while taking aspirin occurs in direct proportion to the individuals’ baseline platelet function. These findings further our understanding as to why patients continue to have thrombotic cardiovascular events despite taking aspirin. See p 2888 (and editorial on p 2865).


*    RISK OF DEATH OR REINFARCTION ASSOCIATED WITH THE USE OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS AND NONSELECTIVE NONSTEROIDAL ANTIINFLAMMATORY DRUGS AFTER ACUTE MYOCARDIAL INFARCTION, by Gislason et al.
up arrowTop
up arrowDUAL-CHAMBER VERSUS SINGLE...
up arrowRESIDUAL ARACHIDONIC ACID...
*RISK OF DEATH OR...
down arrowClinician Update
down arrowImages in Cardiovascular...
down arrowCorrespondence
 
Clinicians are now aware of multiple reports indicating an increased risk of cardiovascular events when patients use nonsteroidal antiinflammatory drugs (NSAIDs), including cyclooxygenase-2 (COX2) inhibitors. The array of articles in the medical and lay press can be overwhelming and at times confusing. In August, 2005, a Special Report on Cyclooxygenase Inhibition and Cardiovascular Risk was published in Circulation (Antman, et al. Cyclooxygenase Inhibition and Cardiovascular Risk. 2005;112:759-770). In this issue, Gislason et al use their analysis of a remarkable database in Denmark to provide much-needed information explicitly regarding patients who have sustained a myocardial infarction and use COX2-selective and -nonselective NSAIDs. They report an increased risk of mortality with selective COX2 inhibitors in all dosages and with nonselective NSAIDs in high dosage. Dr. Judith Hochman provides an insightful editorial emphasizing the strengths and limitations of this latest addition to an evolving story. She concludes that clinicians should temper their enthusiasm for all NSAIDs and provides helpful suggestions for how to use such agents if necessary for pain relief. See p 2906 (and editorial on p 2868).

Visit http://circ.ahajournals.org:


*    Clinician Update
up arrowTop
up arrowDUAL-CHAMBER VERSUS SINGLE...
up arrowRESIDUAL ARACHIDONIC ACID...
up arrowRISK OF DEATH OR...
*Clinician Update
down arrowImages in Cardiovascular...
down arrowCorrespondence
 
South Asians and Cardiovascular Risk: What Clinicians Should Know. See p e924.


*    Images in Cardiovascular Medicine
up arrowTop
up arrowDUAL-CHAMBER VERSUS SINGLE...
up arrowRESIDUAL ARACHIDONIC ACID...
up arrowRISK OF DEATH OR...
up arrowClinician Update
*Images in Cardiovascular...
down arrowCorrespondence
 
Coronary-Subclavian Steal Syndrome Demonstrated by Cardiovascular Magnetic Resonance. See p e930.


Figure 13861
View larger version (171K):
[in this window]
[in a new window]
 

Massive Biventricular Thrombosis as a Consequence of Myocarditis: Findings From 2-Dimensional and Real-Time 3-Dimensional Echocardiography. See p e932.

Transcatheter Right Ventricular Outflow Tract Intervention: The Risk to the Coronary Circulation. See p e934.


*    Correspondence
up arrowTop
up arrowDUAL-CHAMBER VERSUS SINGLE...
up arrowRESIDUAL ARACHIDONIC ACID...
up arrowRISK OF DEATH OR...
up arrowClinician Update
up arrowImages in Cardiovascular...
*Correspondence
 
See p e936.


Related Articles:

The Aspirin Resistance Controversy: Clinical Entity or Platelet Heterogeneity?
Jane E. Freedman
Circulation 2006 113: 2865-2867. [Full Text]

South Asians and Cardiovascular Risk: What Clinicians Should Know
Milan Gupta, Narendra Singh, and Subodh Verma
Circulation 2006 113: e924-e929. [Full Text]

Coronary-Subclavian Steal Syndrome Demonstrated by Cardiovascular Magnetic Resonance
Ping Chai, Mike Dubowitz, and Raad Mohiaddin
Circulation 2006 113: e930-e931. [Full Text]

Massive Biventricular Thrombosis as a Consequence of Myocarditis: Findings From 2-Dimensional and Real-Time 3-Dimensional Echocardiography
Franck Thuny, Jean-François Avierinos, Bertrand Jop, Laurence Tafanelli, Sébastien Renard, Alberto Riberi, Dominique Métras, and Gilbert Habib
Circulation 2006 113: e932-e933. [Full Text]

Transcatheter Right Ventricular Outflow Tract Intervention: The Risk to the Coronary Circulation
Shankar Sridharan, Louise Coats, Sachin Khambadkone, Andrew M. Taylor, and Philipp Bonhoeffer
Circulation 2006 113: e934-e935. [Full Text]

Letter by Saul and Haemmerich Regarding Article "Comparison of Electrode Cooling Between Internal and Open Irrigation in Radiofrequency Ablation Lesion Depth and Incidence of Thrombus and Steam Pop"
J. Philip Saul and Dieter Haemmerich
Circulation 2006 113: e936. [Full Text]

Dual-Chamber Versus Single-Chamber Detection Enhancements for Implantable Defibrillator Rhythm Diagnosis: The Detect Supraventricular Tachycardia Study
Paul A. Friedman, Robyn L. McClelland, William R. Bamlet, Helbert Acosta, David Kessler, Thomas M. Munger, Neal G. Kavesh, Mark Wood, Emile Daoud, Ali Massumi, Claudio Schuger, Stephen Shorofsky, Bruce Wilkoff, and Michael Glikson
Circulation 2006 113: 2871-2879. [Abstract] [Full Text]

What Price Pain Relief?
Judith S. Hochman and Nirav R. Shah
Circulation 2006 113: 2868-2870. [Full Text]




This Article
Free upon publication Free Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles